company background image
2160 logo

MicroPort CardioFlow Medtech SEHK:2160 Voorraadrapport

Laatste prijs

HK$0.82

Marktkapitalisatie

HK$2.0b

7D

-18.0%

1Y

-53.9%

Bijgewerkt

10 Oct, 2024

Gegevens

Financiële gegevens bedrijf +

MicroPort CardioFlow Medtech Corporation

SEHK:2160 Voorraadrapport

Marktkapitalisatie: HK$2.0b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

2160 Overzicht aandelen

MicroPort CardioFlow Medtech Corporation, een bedrijf voor medische apparatuur, houdt zich bezig met onderzoek, ontwikkeling en verkoop van transkatheter en chirurgische oplossingen voor structurele hartaandoeningen in de Volksrepubliek China en internationaal.

Beloningen

Risicoanalyse

Geen risico's gedetecteerd voor 2160 uit onze risicocontroles.

MicroPort CardioFlow Medtech Corporation Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor MicroPort CardioFlow Medtech
Historische aandelenkoersen
Huidige aandelenkoersHK$0.82
52 Week HoogtepuntHK$1.97
52 Week LaagHK$0.58
Bèta0.39
11 maand verandering28.13%
3 maanden verandering-7.87%
1 Jaar Verandering-53.93%
33 jaar verandering-85.93%
5 jaar veranderingn/a
Verandering sinds IPO-95.64%

Recent nieuws en updates

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Recent updates

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Aug 07
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 19
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

May 29
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Apr 05
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Feb 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Jan 18
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Oct 04
Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

May 31
Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

May 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

Apr 06
The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

Feb 08
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Oct 18
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Jun 30
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Jan 21
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

Sep 05
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Jun 07
We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

May 03
Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

Rendement voor aandeelhouders

2160HK Medical EquipmentHK Markt
7D-18.0%-6.8%-3.4%
1Y-53.9%-29.6%15.6%

Rendement versus industrie: 2160 presteerde slechter dan de Hong Kong Medical Equipment -sector, die het afgelopen jaar een rendement van -25.2 % opleverde.

Rendement versus markt: 2160 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is 2160's price volatile compared to industry and market?
2160 volatility
2160 Average Weekly Movement12.3%
Medical Equipment Industry Average Movement9.3%
Market Average Movement8.7%
10% most volatile stocks in HK Market18.3%
10% least volatile stocks in HK Market4.3%

Stabiele aandelenkoers: 2160 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van 2160 is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2010483Jeffrey R Lindstromwww.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corporation, een bedrijf voor medische apparatuur, houdt zich bezig met onderzoek, ontwikkeling en verkoop van transkatheter en chirurgische oplossingen voor structurele hartaandoeningen in de Volksrepubliek China en internationaal. Het bedrijf biedt Vitaflow Aortic Valve System, Alwide Balloon Catheter en Alpass Introducer Set, Angelguide tip-versneden super sti¬ff voerdraad, mitralisklep, tricuspidalisklep en chirurgische kleppen, evenals procedurele accessoires. Het bedrijf biedt ook technisch advies en technische diensten voor klinisch onderzoek met medische hulpmiddelen.

MicroPort CardioFlow Medtech Corporation Samenvatting

Hoe verhouden de winst en inkomsten van MicroPort CardioFlow Medtech zich tot de beurswaarde?
2160 fundamentele statistieken
MarktkapitalisatieHK$1.98b
Inkomsten(TTM)-HK$382.91m
Inkomsten(TTM)HK$420.61m

4.7x

P/S-verhouding

-5.2x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2160 resultatenrekening (TTM)
InkomstenCN¥382.91m
Kosten van inkomstenCN¥111.38m
BrutowinstCN¥271.53m
Overige uitgavenCN¥620.13m
Inkomsten-CN¥348.59m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.14
Brutomarge70.91%
Nettowinstmarge-91.04%
Schuld/Eigen Vermogen Verhouding1.2%

Hoe presteerde 2160 op de lange termijn?

Bekijk historische prestaties en vergelijking